

O-I P E JG174
NOV 28 2003
PATENT & TRADEMARK OFFICE

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>		Application Number	10/616,760
		Filing Date	July 9, 2003
		First Named Inventor	Gelboin, Harry V.
		Art Unit	Unassigned
		Examiner Name	Unassigned
Total Number of Pages in This Submission		Attorney Docket Number	015280-389200US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) <i>(please identify below):</i> Return Postcard PTO/SB/08A & PTO/SB/08B
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.


SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Townsend and Townsend and Crew LLP Nathan S. Cassell Reg. No. 42,396
Signature	<i>Nathan S. Cassell</i>
Date	11-26-03

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Edward Masinas		
Signature	<i>Edward Masinas</i>	Date	11-26-03

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 015280-389200US

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



On 11-26-03

TOWNSEND and TOWNSEND and CREW LLP

By: Edward Masinas

Edward Masinas

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HARRY B. GELBOIN ET AL.

Application No.: 10/616,760

Filed: July 9, 2003

For: AGENTS THAT BIND TO AND
INHIBIT HUMAN CYTOCHROME
P450 2C8, 2C9, 2C18 AND 2C19

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references, can be found in Application No. 09/469,655, filed December 22, 1999 (Attorney Docket No. 015280-389100US). It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Nathan S. Cassell
Reg. No. 42,396

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
NSC:ewm
60087612 v1



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/616,760		
		Filing Date	July 9, 2003		
		First Named Inventor	Gelboin, Harry V.		
		Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	1	of	3	Attorney Docket Number	015280-389200US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	1	6,623,960	09-23-2003	Gelboin et al.	
	2	5,939,530	08-17-1999	Gelboin et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.
60087612 v1



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/616,760	
			Filing Date	July 9, 2003	
			First Named Inventor	Gelboin, Harry V.	
			Art Unit	Unassigned	
			Examiner Name	Unassigned	
Sheet	2	of	3	Attorney Docket Number	015280-389200US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	3	Eichelbaum et al., "Genetically determined differences in drug metabolism as a risk factor in drug toxicity" Toxicology Letters, 64/65:155-122 (1992).	
	4	Gelboin, H. V., "Cytochrome P450 and monoclonal antibodies," Pharmacol Rev, 45(4):413-453, (1993).	
	5	Gelboin et al., "Inhibitory and noninhibitory monoclonal antibodies to human cytochrome P450 2E1," Chem Res Toxicol, 9(6):1023-1030, (1996).	
	6	Gelboin et al., "Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 3A3/4," Biochem Pharmacol, 50(11):1841-1850, (1995).	
	7	Gelboin et al., "A monoclonal antibody inhibitory to human P450 2D6: a paradigm for use in combinatorial determination of individual P450 role in specific drug tissue metabolism," Pharmacogenetics, 7:469-477, (1997).	
	8	Gelboin et al., "Methods in Molecular Biology: Cytochrome P450 Protocols," (Phillips and Shephard, eds.) pp. 227-237, Humana Press, (1998).	
	9	Goldfarb et al., "Cross-reactivity of thirteen monoclonal antibodies with ten vaccinia cDNA expressed rat, mouse and human cytochrome P450s," Biochem Pharmacol, 46:787-790, (1993).	
	10	Goldstein et al., "Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans," Biochemistry, 33:1743-1752 (1994)	
	11	Gonzalez, F.J., "Cytochromes P450: Metabolic and Toxicological Aspects," (Ioannides, C., ed.) pp. 183-210, CRC Press (1996)	
	12	Gonzalez et al., "Pharmacogenetic phenotyping and genotyping", Clin. Pharmacokin, 26(1):59-70 (1994).	
	13	Gonzalez et al., "Role of Human Cytochrome P-450s in Risk Assessment and Susceptibility to Environmentally Based Disease," J. Toxicol. and Environmental Health, 40:289-308, (1993).	
	14	Gonzalez et al., "Expression of mammalian cytochrome P450 using vaccinia virus," Methods Enzymol, 206:85-92 (1991a).	
	15	Gonzalez et al., "Expression of mammalian cytochrome P450 using baculovirus," Methods Enzymol, 206:93-99, (1991b).	
	16	Guengerich et al., "Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes," Chem Res Toxicol, 4(4):391-407, (1991).	
	17	Haining et al., "Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and 1359L mutant forms, Arch Biochem Biophys, 333:447-458, (1996)	
	18	Kupfer et al., "Mephenytoin hydrolation deficiency: Kinetics after repeated doses," Clin. Pharmacol. Ther., 35:33 (1984).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/616,760	
			Filing Date	July 9, 2003	
			First Named Inventor	Gelboin, Harry V.	
			Art Unit	Unassigned	
			Examiner Name	Unassigned	
Sheet	3	of	3	Attorney Docket Number	015280-389200US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	19	Madsen et al., "Imipramine demethylation in vivo: Impact of CYP1A2, CYP2C19, and CYP3A4," Clin. Pharmacol. Ther., 61:319-324 (1997)	
	20	Miners et al., "Cytochrome P452C9: An enzyme of major importance in human drug metabolism," Br. J. Clin. Pharmacol, 45:525-538 (1998).	
	21	Nasu et al., "Genetic analysis of CYP2C9 polymorphism in a Japanese population, Pharmacogenetics, 7:405-409 (1997).	
	22	Pierce Chemical Company catalogue, "Antibody fragmentation," Rockford IL (1994).	
	23	Rendic et al., "Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors," Drug Metab. Rev, 29:413-580, (1997).	
	24	Rettie et al., "Impaired (S)-warfarin metabolism catalyzed by the R144C allelic variant of CYP2C9," Pharmacogenetics, 4:39-42 (1994).	
	25	Rudikoff et al. PNAS, 79:1979-1983 (1982).	
	26	Sai et al., "An inhibitory monoclonal antibody to human cytochrome P450 2A6 defines its role in the metabolism of coumarin, 7-ethoxycoumarin and 4-nitroanisole in human liver," Pharmacogenetics, 9:229-237 (1999).	
	27	Shou et al., "Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 to human drug metabolism" Eur. J. Pharmacol., 394(203):199-209, (2000).	
	28	Sullivan-Klose et al., "The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism, Pharmacogenetics, 6:341-349 (1996).	
	29	Veronese et al., "Tolbutamide and phenytoin hydroxylation's by cDNA-expressed human liver cytochrome P450 2C9, Biochemical Biophysical Research Communications, 175:1112-1118 (1991).	
	30	Washida et al., "Preparation of an activity-inhibiting monoclonal antibody against human placental aromatase cytochrome P450," Steroids, 61:126-132 (1996).	
	31	Yamazaki et al., "7-ethoxycoumarin O-deethylation catalyzed by cytochromes P450 1A2 and 2E1 in human liver microsomes," Biochem. Pharmacol., 51:313-319 (1996).	
	32	Yamazaki et al., "Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes, Biochem Pharmacol, 56:243-251 (1998).	
	33	Yang et al., "Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin and imipramine metabolism" Drug Metab. Dispos., 27(1):102-109, (1999).	
	34	Yang et al., "Inhibitory monoclonal antibodies to human cytochrome P450 1A2: Analysis of phenacetin O-deethylation in human liver," Pharmacogenetics, 8:375-382 (1998).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.